Boditech Med Inc. (206640.KQ)

KRW 16650.0

(-0.3%)

Operating Income Summary of Boditech Med Inc.

Boditech Med Inc.'s latest annual operating income in 2023 was 33.44 Billion KRW , up 14.84% from previous year.
Boditech Med Inc.'s latest quarterly operating income in 2024 Q2 was 8.76 Billion KRW , up 59.35% from previous quarter.
Boditech Med Inc. reported an annual operating income of 23.31 Billion KRW in 2022, down -53.95% from previous year.
Boditech Med Inc. reported an annual operating income of 50.63 Billion KRW in 2021, down -22.8% from previous year.
Boditech Med Inc. reported a quarterly operating income of 8.76 Billion KRW for 2024 Q2, up 59.35% from previous quarter.
Boditech Med Inc. reported a quarterly operating income of 7.54 Billion KRW for 2023 Q2, up 59.33% from previous quarter.

Annual Operating Income Chart of Boditech Med Inc. (2023 - 2015)

Historical Annual Operating Income of Boditech Med Inc. (2023 - 2015)

Year	Operating Income	Operating Income Growth
2023	33.44 Billion KRW	14.84%
2022	23.31 Billion KRW	-53.95%
2021	50.63 Billion KRW	-22.8%
2020	65.58 Billion KRW	431.96%
2019	12.32 Billion KRW	89.84%
2018	6.49 Billion KRW	126.01%
2017	2.87 Billion KRW	-76.8%
2016	12.38 Billion KRW	0.09%
2015	12.37 Billion KRW	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	5.81 Billion KRW	-4.37%
2024 Q2	8.76 Billion KRW	59.35%
2023 Q2	7.54 Billion KRW	59.33%
2023 FY	26.77 Billion KRW	14.84%
2023 Q3	8.41 Billion KRW	11.58%
2023 Q1	4.73 Billion KRW	-31.99%
2023 Q4	6.07 Billion KRW	-27.79%
2022 FY	23.31 Billion KRW	-53.95%
2022 Q1	8.77 Billion KRW	56.12%
2022 Q2	2.91 Billion KRW	-66.82%
2022 Q3	4.61 Billion KRW	58.45%
2022 Q4	6.96 Billion KRW	50.92%
2021 FY	50.63 Billion KRW	-22.8%
2021 Q3	16.01 Billion KRW	-3.5%
2021 Q1	13.15 Billion KRW	-54.52%
2021 Q2	16.59 Billion KRW	26.12%
2021 Q4	5.62 Billion KRW	-64.91%
2020 Q2	15.02 Billion KRW	521.77%
2020 FY	65.58 Billion KRW	431.96%
2020 Q4	28.93 Billion KRW	47.29%
2020 Q3	19.64 Billion KRW	30.74%
2020 Q1	2.41 Billion KRW	-47.3%
2019 Q4	4.58 Billion KRW	13.07%
2019 FY	12.32 Billion KRW	89.84%
2019 Q1	3.64 Billion KRW	27.46%
2019 Q2	2.72 Billion KRW	-25.32%
2019 Q3	4.05 Billion KRW	48.77%
2018 FY	6.49 Billion KRW	126.01%
2018 Q4	2.86 Billion KRW	45.6%
2018 Q2	1.24 Billion KRW	193.19%
2018 Q3	1.96 Billion KRW	58.39%
2018 Q1	423.45 Million KRW	126.39%
2017 Q2	1.64 Billion KRW	-37.56%
2017 Q1	2.62 Billion KRW	67.22%
2017 FY	2.87 Billion KRW	-76.8%
2017 Q4	-1.6 Billion KRW	-876.51%
2017 Q3	206.66 Million KRW	-87.41%
2016 Q2	4.25 Billion KRW	66.8%
2016 Q4	1.57 Billion KRW	-60.76%
2016 Q1	2.55 Billion KRW	-18.82%
2016 Q3	4 Billion KRW	-5.83%
2016 FY	12.38 Billion KRW	0.09%
2015 Q4	3.14 Billion KRW	-21.53%
2015 FY	12.37 Billion KRW	0.0%
2015 Q3	4 Billion KRW	18.22%
2015 Q1	1.84 Billion KRW	0.0%
2015 Q2	3.38 Billion KRW	84.09%

Peer Operating Income Comparison of Boditech Med Inc.

Name	Operating Income	Operating Income Difference
HLB Pharmaceutical Co., Ltd	-19.54 Billion KRW	271.133%
CMG Pharmaceutical Co., Ltd.	5.72 Billion KRW	-484.138%
Celltrion Pharm, Inc.	36.07 Billion KRW	7.285%
Huons Global Co., Ltd.	122.92 Billion KRW	72.794%
DongKook Pharmaceutical Co., Ltd.	66.87 Billion KRW	49.99%
Enzychem Lifesciences Corporation	-14.35 Billion KRW	332.953%
Humedix Co., Ltd.	37.31 Billion KRW	10.365%
EuBiologics Co., Ltd.	7.69 Billion KRW	-334.376%
FutureChem Co.,Ltd	-8.4 Billion KRW	497.757%
Huons Co., Ltd.	59.79 Billion KRW	44.07%
BNC Korea Co., Ltd.	10.81 Billion KRW	-209.123%
AptaBio Therapeutics Inc.	-16.37 Billion KRW	304.251%